The antiviral effects of the cationic acrylate polymer E100 on a panel of lipid-enveloped viruses and the interactions involved are studied. The treatment of several common viruses with E100 induced a dose-dependent inhibition of the infectivity of viruses below the detection limit of the assays employed. Similarly, the treatment of human sera infected with HIV or HCV reduced virus RNA plasma levels to undetectable values. This implies that Eudragit E100 can interact with enveloped viruses, even in the presence of proteins, through a mechanism that is not reversed by titration of the positively charged groups of the polymer, opening the possibility to remove viral particles with the polymer as it is eliminated.

The method described is an effective way of preparing large quantities of IVIG (lyophilized and liquid) which fulfils the standard requirements of both the European Pharmacopoeia and the World Health Organization.

Cover: The scheme represents the sequential steps of E100 biopolymer interaction with enveloped viruses. The E100 interacts, neutralizes and allows to remove the virus through the formation a non-infective E100-virus complex. Further details can be found in the article by R

Background: Immunoglobulin (IG) products, including intravenous (IVIG) or subcutaneous (SCIG) immunoglobulins are considered safe and effective for medical therapy; however, a sudden and unexpected increase in thromboembolic events (TE) after administration of certain batches of IVIG products has been attributed to the presence of activated coagulation factors, mainly factor XIa. Our aims were to examine the presence of enduring procoagulant activity during the manufacturing process of IGs, with special focus on monitoring factor XIa, and to evaluate the presence of in vitro procoagulant activity attributed to coagulation factors in different lots of IVIG and SCIG. Methods: Samples of different steps of IG purification, 19 lots of IVIG and 9 of SCIG were analyzed and compared with 1 commercial preparation of IVIG and 2 of SCIG, respectively. Factors II, VII, IX, XI and XIa and non-activated partial thromboplastin time (NAPTT) were assayed. Results: The levels of factors II, VII, IX, X and XI were non-quantifiable once fraction II had been re-dissolved and in all analyzed lots of IVIG and SCIG. The level of factor XIa at that point was under the detection limits of the assay, and NAPTT yielded values greater than the control during the purification process. In SCIG, we detected higher concentrations of factor XIa in the commercial products, which reached values up to 5 times higher than the average amounts found in the 9 batches produced by UNC-Hemoderivados. Factor XIa in commercial IVIG reached levels slightly higher than those of the 19 batches produced by UNC-Hemoderivados. Conclusion: IVIG and SCIG manufactured by UNC-Hemoderivados showed a lack of thrombogenic potential, as demonstrated not only by the laboratory data obtained in this study but also by the absence of any reports of TE registered by the post marketing pharmacovigilance department.

No abstract